Positive 15-month results with Diamyd® in Type 1 diabetes
When all patients have been followed for 15 months in the diabetes trial DIAGNODE-1, where the diabetes vaccine Diamyd® is given directly into the lymph node, a clearly positive and clinically relevant effect is seen in improving the clinical course and maintaining the endogenous insulin production in newly diagnosed type 1 diabetes.Diamyd Medical today announced that 15-month results from the DIAGNODE-1 trial show a positive and clinically relevant effect on the three prioritized efficacy endpoints - insulin production, long-term blood sugar level (HbA1c) and external insulin requirement.